Sun Pharma inks pact with Bayer to sell drug for chronic kidney disease
Under the terms of the agreement, Bayer has granted non-exclusive rights to Sun Pharma to market and distribute a second Finerenone product under the brand name Lyvelsa. Finerenone was first launched by Bayer under the brand name Kerendia in 2022.
![Sun Pharma inks pact with Bayer to sell drug for chronic kidney disease](https://cdn.zeebiz.com/sites/default/files/2024/01/17/276666-news-1.jpg?im=FitAndFill=(1200,900))
"This partnership underscores our commitment to make innovative medicines available to patients in India," Sun Pharma India Business CEO Kirti Ganorkar said in a statement. Image Gathered from Reuters.